# ET-01 in Subjects With Lateral Canthal Lines, LCL-210

> **NCT04985916** · PHASE2 · COMPLETED · sponsor: **Eirion Therapeutics Inc.** · enrollment: 280 (actual)

## Conditions studied

- Lateral Canthal Lines, LCL
- Crow's Feet

## Interventions

- **BIOLOGICAL:** Vehicle
- **BIOLOGICAL:** botulinum toxin, Type A

## Key facts

- **NCT ID:** NCT04985916
- **Lead sponsor:** Eirion Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-19
- **Primary completion:** 2024-02-08
- **Final completion:** 2024-02-08
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04985916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04985916, "ET-01 in Subjects With Lateral Canthal Lines, LCL-210". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04985916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*